 |
|
Aggressive Therapy for NeurosarcoidosisLong-term Follow-up of 48 Treated Patients
Thomas F. Scott, MD;
Kristin Yandora, DO;
April Valeri, BA;
Carol Chieffe, RN, MSCN;
Carol Schramke, PhD
Arch Neurol. 2007;64(5):691-696.
Background Neurosarcoidosis (NS) is a relatively rare neurologic disorder for which no accepted treatment guidelines are available. Treatment with corticosteroids has been described as the primary means of controlling progressive symptoms. However, some physicians have recently advocated early intervention with alternative immunosuppressive therapies in patients who present with disabling symptoms.
Objective To investigate our experience during the last decade regarding alternative immunosuppressive treatments, including corticosteroids and alternative therapies, in patients with NS.
Design Observational, retrospective, consecutive case series with longitudinal follow-up.
Setting Allegheny Neurological Clinic.
Patients Seventy-eight patients with sarcoidosis were evaluated and classified as having possible, probable, or definite NS according to accepted criteria. Five cases of isolated NS were also included.
Main Outcome Measures Patients with probable, definite, or isolated NS were scored before treatments and at final follow-up using estimated modified Rankin scores and the Disease Steps in Multiple Sclerosis scales.
Results Forty-three patients were categorized as having either definite or probable NS according to accepted criteria and an additional 5 as having isolated NS. Thirty patients were categorized as having possible NS and were not included in the analysis of treatment response. Patients had a mean ± SD number of visits of 7.2 ± 6.4 and were followed up for a mean ± SD of 44.1 ± 43.6 months. Twenty patients were treated with pulse and/or maintenance corticosteroids alone. Twenty-six patients were treated with alternative immunosuppressive medications, with 23 of them receiving these medications at the time of diagnosis or within 6 months of the diagnosis of NS. Of the patients treated with alternative immunosuppressive therapies, 18 (69%) improved, 4 (15%) remained stable, and 4 (15%) worsened (including 1 death). Of the patients treated with corticosteroids alone, 7 (35%) improved, 11 (55%) remained stable, and 2 (10%) worsened. Two patients received no treatment.
Conclusions Approximately half of all patients with NS seen at our clinic were believed to have disabling disease and to be at high risk for disease progression. These high-risk patients were treated with corticosteroids plus alternative immunosuppressive therapy, and favorable outcomes were obtained in almost all patients. Toxic effects related to treatments were minimal.
Author Affiliations: Department of Neurology, Drexel University College of Medicine (Drs Scott and Schramke), Department of Neurology, Allegheny General Hospital (Dr Yandora and Mss Valeri and Chieffe), and Allegheny Neurological Associates (Mss Valeri and Chieffe), Pittsburgh, Pa.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Presentations and outcomes of neurosarcoidosis: a study of 54 cases
Pawate et al.
QJM 2009;102:449-460.
ABSTRACT
| FULL TEXT
Neurosarcoidosis with necrotising sarcoid granulomatosis mimicking meningiomatosis cerebri: case report and literature search
Savage et al.
BMJ Case Reports 2009;2009:bcr1120081187-bcr1120081187.
ABSTRACT
| FULL TEXT
Sarcoidosis presenting with hydrocephalus
Brouwer et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:550-551.
FULL TEXT
Case 6-2009 -- A 37-Year-Old Woman with Vertigo, Facial Weakness, and a Generalized Seizure
Cros et al.
NEJM 2009;360:802-809.
FULL TEXT
Clinical Reasoning: A 42-year-old man with sequential monocular visual loss
Prasad et al.
Neurology 2008;71:e43-e49.
FULL TEXT
Case 25-2008 -- A 43-Year-Old Man with Fatigue and Lesions in the Pituitary and Cerebellum
Mills et al.
NEJM 2008;359:736-747.
FULL TEXT
Sarcoidosis
Iannuzzi et al.
NEJM 2007;357:2153-2165.
FULL TEXT
|
